截止1993年，Proleukin仍是唯一获得批准的IL-2药物，但此时罗氏也开发了自己的修饰重组的IL-2（在氨基端增加了甲硫氨酸）商品名为teceleukin，and Glaxo was developing a version called bioleukin, with a methionine added at is N-terminal and residue 125 replaced with alanine. Dozens of clinical trials had been conducted of recombinant or purified IL-2, alone, in combination with other drugs, or using cell therapies, in which cells were taken from patients, activated with IL-2, then reinfused.Novartis acquired Chiron in 2006 and sold the aldesleukin business to Prometheus Laboratories in 2010.
^Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT. Pharmacologic administration of interleukin-2. Annals of the New York Academy of Sciences. December 2009, 1182: 14–27. PMID 20074271. doi:10.1111/j.1749-6632.2009.05160.x.
^Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. Journal of the American Academy of Dermatology. October 2015, 73 (4): 645–54. PMID 26259990. doi:10.1016/j.jaad.2015.06.060.